Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Ca...
October 01 2019 - 6:01PM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
safety and efficacy data for JTX-4014 and a clinical trial in
progress description of the vopratelimab Phase 2 EMERGE study will
be presented in two poster sessions at the Society for
Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, being held
November 6-10, 2019 in National Harbor, Maryland.
Poster Details:
Poster Title: Phase 1 First in Human Study of Programmed
Cell Death Receptor-1(PD-1) Inhibitor Monoclonal Antibody (mAb)
JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor
Malignancies (Safety, efficacy and recommended Phase 2
dose will be presented)Author: Kyriakos P. Papadopoulos, M.D.
Co-Director of Clinical Research, START, San Antonio, TexasPoster
Session Number: P439Location: Poster Hall (Prince George AB)Date
and Time: Friday, November 8, 2019; 7:00am–8pm ET
Poster Title: Phase 2 Multicenter Trial of ICOS Agonist
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor
Experienced Adult Subjects with Non-Small Cell Lung Cancer or
Urothelial Cancer (EMERGE) (This is a trial in progress
poster only)Author: Russell Pachynski M.D., Assistant Professor of
Medicine, Division of Medical Oncology, Washington University
School of Medicine, St. Louis, MissouriPoster Session Number:
P438Location: Poster Hall (Prince George AB)Date and Time:
Saturday, November 9, 2019; 7:00am–8:30pm ET
About JTX-4014JTX-4014 is a well-characterized
fully human IgG4 monoclonal antibody designed to block binding to
PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in
combination with its pipeline of future product candidates. Jounce
completed enrollment in the Phase 1 clinical trial of JTX-4014.
About Vopratelimab Jounce’s lead product
candidate, vopratelimab (formerly JTX-2011), is a clinical-stage
monoclonal antibody that binds to and activates ICOS, the Inducible
T cell CO Stimulator, a protein on the surface of certain T cells
commonly found in many solid tumors. Vopratelimab was previously
assessed in the Phase 1/2 ICONIC trial and was found to be safe and
well-tolerated, alone and in combination with each of the anti-PD-1
antibodies nivolumab and pembrolizumab, and ipilimumab, an antibody
that binds to CTLA-4. In June 2018, Jounce reported Response
Evaluation Criteria in Solid Tumors (RECIST) responses and other
tumor reductions as determined by investigator assessment that were
associated with an ICOS pharmacodynamic biomarker, ICOS hi CD4 T
cells. In April 2019, Jounce reported data on patients in the
ICONIC trial with the emergence of ICOS hi CD4 T cells who had
improved progression free survival and overall survival compared to
patients with ICOS lo CD4 T cells; this was based on an analysis of
a subgroup of patients with multiple solid tumor types including
PD-1 inhibitor naive and PD-1 inhibitor experienced patients.
Vopratelimab is currently being assessed in the Phase 2 EMERGE
clinical trial in combination with ipilimumab in patients with
non-small cell lung cancer or urothelial cancer who have progressed
on or after PD-1/PD-L1 inhibitor therapies.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients through a biomarker-driven approach. Through
the use of its Translational Science Platform, Jounce first focuses
on specific cell types within the human tumor microenvironment to
prioritize targets, and then identifies related biomarkers designed
to match the right immunotherapy to the right patient. Jounce is
developing two clinical-stage programs as well as advancing and
building out its broad and wholly-owned discovery pipeline of
immuno-oncology targets, including those expressed on T-regulatory
cells, macrophages and stromal cells. Jounce’s lead product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS and is currently being assessed in a Phase 2
clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in
combination with future pipeline products, and Jounce has completed
enrollment in the JTX-4014 Phase 1 clinical trial. In addition,
Jounce has exclusively licensed worldwide rights to JTX-8064, a
LILRB2 receptor antagonist, to Celgene. For more information,
please visit www.jouncetx.com.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Kathryn MorrisThe Yates
Network914-204-6412kathryn@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From May 2023 to May 2024